Literature DB >> 375751

Role of ligandin in transfer of bilirubin from plasma into liver.

A W Wolkoff, C A Goresky, J Sellin, Z Gatmaitan, I M Arias.   

Abstract

Multiple-indicator dilution studies of labeled bilirubin uptake were carried out on isolated perfused rat livers with variable ligandin concentrations (from normal and thyroidectomized animals with and without phenobarbital pretreatment). Ligandin concentrations, measured immunologically, increased 25% after thyroidectomy and approximately doubled after phenobarbital pretreatment but decreased to normal during perfusion in the thyroidectomized nonpretreated group. A distributed two-compartment model was fitted to the dilution data and estimates of influx, efflux, and sequestration coefficients were obtained. Influx and sequestration coefficients did not vary significantly between the groups. Efflux coefficients were significantly smaller (P less than 0.001), and hepatic ligandin concentrations were significantly larger (p less than 0.001) in phenobarbital-treated rats than in other groups. The efflux coefficient varied inversely with ligandin concentration and the volume of distribution in tissue, as perceived from the plasma space, increased in proportion to the concentration of ligandin. The increased net uptake of tracer bilirubin by the liver of phenobarbital-pretreated animals is due to decreased tracer efflux secondary to the increase in intracellular binding of bilirubin by ligandin.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 375751     DOI: 10.1152/ajpendo.1979.236.6.E638

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  41 in total

1.  Modeling of hepatic elimination and organ distribution kinetics with the extended convection-dispersion model.

Authors:  M S Roberts; Y G Anissimov
Journal:  J Pharmacokinet Biopharm       Date:  1999-08

2.  Kinetic analysis of the dose-dependent hepatic handling of 1-anilino-8-naphthalene sulfonate in rats.

Authors:  Y B Chung; S Miyauchi; Y Sugiyama; H Harashima; T Iga; M Hanano
Journal:  J Pharmacokinet Biopharm       Date:  1990-08

3.  Residence time distributions of solutes in the perfused rat liver using a dispersion model of hepatic elimination: 1. Effect of changes in perfusate flow and albumin concentration on sucrose and taurocholate.

Authors:  M S Roberts; S Fraser; A Wagner; L McLeod
Journal:  J Pharmacokinet Biopharm       Date:  1990-06

Review 4.  Covalent and noncovalent protein binding of drugs: implications for hepatic clearance, storage, and cell-specific drug delivery.

Authors:  D K Meijer; P van der Sluijs
Journal:  Pharm Res       Date:  1989-02       Impact factor: 4.200

5.  Drug- and Drug Abuse-Associated Hyperbilirubinemia: Experience With Atazanavir.

Authors:  Jayanta Roy-Chowdhury; Namita Roy-Chowdhury; Irving Listowsky; Allan W Wolkoff
Journal:  Clin Pharmacol Drug Dev       Date:  2017-03

6.  Dynamic determination of kinetic parameters for the interaction between polypeptide hormones and cell-surface receptors in the perfused rat liver by the multiple-indicator dilution method.

Authors:  H Sato; Y Sugiyama; Y Sawada; T Iga; S Sakamoto; T Fuwa; M Hanano
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

7.  An understanding of flow- and diffusion-limited vs. carrier-mediated hepatic transport: a simulation study.

Authors:  W P Geng; K Poon; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1995-08

8.  Immunological studies of an organic anion-binding protein isolated from rat liver cell plasma membrane.

Authors:  A W Wolkoff; A Sosiak; H C Greenblatt; J Van Renswoude; R J Stockert
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

9.  Hepatic microcirculation in the perfused cirrhotic rat liver.

Authors:  F Varin; P M Huet
Journal:  J Clin Invest       Date:  1985-11       Impact factor: 14.808

10.  The effect of hepatic regeneration on the expression of the glutathione S-transferases.

Authors:  S J Lee; T D Boyer
Journal:  Biochem J       Date:  1993-07-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.